Extracellular Vesicles and Their Correlation with Inflammatory Factors in an Experimental Model of Steatotic Liver Disease Associated with Metabolic Dysfunction

Abstract

Background/Aims:

Extracellular vesicles (EVs) are promising as a biomarker of metabolic dysfunction associated steatotic liver disease (MASLD). The objective is to study EVs and their involvement in MASLD concerning the disease's pathogenesis and progression characteristics.

Methods:

Male adult Sprague Dawley rats were randomly assigned into two experimental models of MASLD: MASLD-16 and MASLD-28, animals received a choline-deficient high-fat diet (CHFD) and Control-16 and Control-28, animals received a standard diet (SD) for 16 and 28 weeks, respectively. Biological samples from these animal models were used, as well as previously registered variables. EVs from hepatic tissue were characterized using confocal microscopy. EVs were isolated through differential ultracentrifugation from serum and characterized using NanoSight. The data from the EVs were correlated with biochemical, molecular, and histopathological parameters.

Results:

Liver EVs were identified through the flotillin-1 protein. EVs were isolated from the serum of all groups. There was a decrease of EVs concentration in MASLD-28 in comparison with Control-28 (P < 0.001) and a significant increase in EVs concentration in Control-28 compared with Control-16 (P < 0.001). There was a strong correlation between serum EVs concentration with hepatic gene expression of interleukin (Il)6 (r ² = 0.685, P < 0.05), Il1b (r ² = 0.697, P < 0.05) and tumor necrosis factor-alpha (Tnfa; r ² = 0.636, P < 0.05) in MASLD-16. Moreover, there was a strong correlation between serum EVs size and Il10 in MASLD-28 (r ² = 0.762, P < 0.05).

Conclusion:

The concentration and size of EVs correlated with inflammatory markers, suggesting their involvement in the systemic circulation, cellular communication, and development and progression of MASLD, demonstrating that EVs have the potential to serve as noninvasive biomarkers for MASLD diagnosis and prognosis.

Get full access to this article

View all access options for this article.

References

Rinella

, Lazarus

, Ratziu

, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol, 2023; 79(6):1542–1556; doi: 10.1016/j.jhep.2023.06.003

Pouwels

, Sakran

, Graham

, et al. Non-alcoholic fatty liver disease (NAFLD): A review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord, 2022; 22(1):63; doi: 10.1186/s12902-022-00980-1

, Zou

, Yeo

, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2019; 4(5):389–398; doi: 10.1016/S2468-1253(19)30039-1

Younossi

, Golabi

, Paik

, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review. Hepatology, 2023; 77(4):1335–1347; doi: 10.1097/HEP.0000000000000004

Targher

, Corey

, Byrne

. NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment. Diabetes Metab, 2021; 47(2):101215; doi: 10.1016/j.diabet.2020.101215

Vetrano

, Rinaldi

, Mormone

, et al. Non-alcoholic fatty liver disease (NAFLD), type 2 diabetes, and non-viral hepatocarcinoma: pathophysiological mechanisms and new therapeutic strategies. Biomedicines, 2023; 11(2):468; doi: 10.3390/biomedicines11020468

Caturano

, Acierno

, Nevola

, et al. Non-alcoholic fatty liver disease: From pathogenesis to clinical impact. Processes, 2021; 9(1):135; doi: 10.3390/pr9010135

Nassir

. NAFLD: Mechanisms, treatments, and biomarkers. Biomolecules, 2022; 12(6):824; doi: 10.3390/biom12060824

Piazzolla

, Mangia

. Noninvasive diagnosis of NAFLD and NASH. Cells, 2020; 9(4):1005; doi: 10.3390/cells9041005

10.

Povero

, Eguchi

, Li

, et al. Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease. PLoS One, 2014; 9(12):e113651; doi: 10.1371/journal.pone.0113651

11.

Hirsova

, Ibrahim

, Krishnan

, et al. Lipid-induced signaling causes release of inflammatory extracellular vesicles from hepatocytes. Gastroenterology, 2016; 150(4):956–967; doi: 10.1053/j.gastro.2015.12.037

12.

Hirsova

, Ibrahim

, Verma

, et al. Extracellular vesicles in liver pathobiology: Small particles with big impact. Hepatology, 2016; 64(6):2219–2233; doi: 10.1002/hep.28814

13.

Newman

, Sorich

, Rowland

. Role of extracellular vesicles in the pathophysiology, diagnosis and tracking of non-alcoholic fatty liver disease. J Clin Med, 2020; 9(7):2032; doi: 10.3390/jcm9072032

14.

Srinivas

, Suresh

, Kaur

, et al. The promise of small particles: Extracellular vesicles as biomarkers in liver pathology. J Physiol, 2023; 601(22):4953–4971; doi.org/10.1113/JP283074

15.

Longo

, Tonin Ferrari

, Rampelotto

, et al. Gut dysbiosis and increased intestinal permeability drive microRNAs, NLRP-3 inflammasome and liver fibrosis in a nutritional model of non-alcoholic steatohepatitis in adult male Sprague Dawley rats. Clin Exp Gastroenterol, 2020; 13:351–368; doi: 10.2147/CEG.S262879

16.

de Freitas

LBR

, Longo

, Filippi-Chiela

, et al. Ornithine aspartate and vitamin-E combination has beneficial effects on cardiovascular risk factors in an animal model of nonalcoholic fatty liver disease in rats. Biomolecules, 2022; 12(12):1773; doi: 10.3390/biom12121773

17.

Longo

, Rampelotto

, Filippi-Chiela

, et al. Gut dysbiosis and systemic inflammation promote cardiomyocyte abnormalities in an experimental model of steatohepatitis. World J Hepatol, 2021; 13(12):2052–2070; doi: 10.4254/wjh.v13.i12.2052

18.

Jiang

, Chen

, Wang

, et al. Hepatocyte-derived extracellular vesicles promote endothelial inflammation and atherogenesis via microRNA-1. J Hepatol, 2020; 72(1):156–166; doi: 10.1016/j.jhep.2019.09.014

19.

, Liu

, Mauer

, et al. Characterization of cellular sources and circulating levels of extracellular vesicles in a dietary murine model of nonalcoholic steatohepatitis. Hepatol Commun, 2019; 3(9):1235–1249; doi: 10.1002/hep4.1404

20.

Povero

, Feldstein

. Novel molecular mechanisms in the development of non-alcoholic steatohepatitis. Diabetes Metab J, 2016; 40(1):1–11; doi: 10.4093/dmj.2016.40.1.1

21.

Crescitelli

, Lässer

, Jang

, et al. Subpopulations of extracellular vesicles from human metastatic melanoma tissue identified by quantitative proteomics after optimized isolation. J Extracell Vesicles, 2020; 9(1):1722433; doi: 10.1080/20013078.2020.1722433

22.

Kowal

, Arras

, Colombo

, et al. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. Proc Natl Acad Sci U S A, 2016; 113(8):E968–E977; doi: 10.1073/pnas.1521230113

23.

Peiseler

, Tacke

. Inflammatory mechanisms underlying nonalcoholic steatohepatitis and the transition to hepatocellular carcinoma. Cancers (Basel), 2021; 13(4):730; doi: 10.3390/cancers13040730

24.

Hernández

, Geng

, Sepúlveda

, et al. Chemical hypoxia induces pro-inflammatory signals in fat-laden hepatocytes and contributes to cellular crosstalk with Kupffer cells through extracellular vesicles. Biochim Biophys Acta Mol Basis Dis, 2020; 1866(6):165753; doi: 10.1016/j.bbadis.2020.165753

25.

Buzzetti

, Pinzani

, Tsochatzis

. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metab Clin Exp, 2016; 65(8):1038–1048; doi: 10.1016/j.metabol.2015.12.012

26.

Alabdulaali

, Al-Rashed

, Al-Onaizi

, et al. Macrophages and the development and progression of non-alcoholic fatty liver disease. Front Immunol, 2023; 14:1195699; doi: 10.3389/fimmu.2023.1195699

27.

Liu

, Pan

, Cao

, et al. Lipotoxic hepatocyte-derived exosomal miR-192–195p activates macrophages via Rictor/Akt/FoxO1 signaling in NAFLD. Hepatology, 2020; 72(2):454–469; doi: 10.1002/hep.31050

28.

Asrih

, Jornayvaz

. Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance. J Endocrinol, 2013; 218(3):R25–R36; doi: 10.1530/JOE-13-0201

29.

Srinivas

, Suresh

, Santhekadur

, et al. Extracellular vesicles as inflammatory drivers in NAFLD. Front Immunol, 2021; 11:627424; doi: 10.3389/fimmu.2020.627424

30.

Zhang

, Zhang

, et al. Mesenchymal stem cells derived extracellular vesicles alleviate traumatic hemorrhagic shock induced hepatic injury via IL-10/PTPN22-mediated M2 Kupffer cell polarization. Front Immunol, 2022; 12:811164; doi: 10.3389/fimmu.2021.811164

31.

Maiti

, Peruzzaro

, Kolli

, et al. Transplantation of mesenchymal stem cells overexpressing interleukin-10 induces autophagy response and promotes neuroprotection in a rat model of TBI. J Cell Mol Med, 2019; 23(8):5211–5224; doi: 10.1111/jcmm.14396

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.04 MB

0.10 MB

0.16 MB